Provider: NIHR Journals Library Content:text/plain; charset="UTF-8" TY - ELEC LB - 1. AU - National Audit Office TI - Services for People with Rheumatoid Arthritis UR - www.nao.org.uk/report/services-for-people-with-rheumatoid-arthritis/ M1 - November 2018 ER - TY - GEN LB - 2. AU - Dickson, JL AU - Lanyon, P AU - Wise, E TI - Making a Diagnosis of Rheumatoid Arthritis UR - www.nras.org.uk/diagnosis Y2 - October 2018 ER - TY - JOUR LB - 3. AU - Picerno, V AU - Ferro, F AU - Adinolfi, A AU - Valentini, E AU - Tani, C AU - Alunno, A TI - One year in review: the pathogenesis of rheumatoid arthritis J2 - Clin Exp Rheumatol PY - 2015 VL - 33 SP - 551 EP - 558 ER - TY - JOUR LB - 4. AU - Scott, IC AU - Steer, S AU - Lewis, CM AU - Cope, AP TI - Precipitating and perpetuating factors of rheumatoid arthritis immunopathology: linking the triad of genetic predisposition, environmental risk factors and autoimmunity to disease pathogenesis J2 - Best Pract Res Clin Rheumatol PY - 2011 VL - 25 SP - 447 EP - 468 UR - https://doi.org/10.1016/j.berh.2011.10.010 ER - TY - ELEC LB - 5. AU - National Rheumatoid Arthritis Society TI - What is the Cause of Rheumatoid Arthritis? Non-Genetic Factors UR - www.nras.org.uk/what-is-the-cause-of-rheumatoid-arthritis-non-genetic-factors M1 - October 2018 ER - TY - JOUR LB - 6. AU - Karlson, EW AU - Mandl, LA AU - Hankinson, SE AU - Grodstein, F TI - Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses’ Health Study J2 - Arthritis Rheum PY - 2004 VL - 50 SP - 3458 EP - 3467 UR - https://doi.org/10.1002/art.20621 ER - TY - JOUR LB - 7. AU - Sugiyama, D AU - Nishimura, K AU - Tamaki, K AU - Tsuji, G AU - Nakazawa, T AU - Morinobu, A AU - Kumagai, S TI - Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies J2 - Ann Rheum Dis PY - 2010 VL - 69 SP - 70 EP - 81 UR - https://doi.org/10.1136/ard.2008.096487 ER - TY - ELEC LB - 8. AU - National Rheumatoid Arthritis Society TI - The Genetics of Rheumatoid Arthritis UR - www.nras.org.uk/the-genetics-of-rheumatoid-arthritis M1 - December 2018 ER - TY - JOUR LB - 9. AU - Philippou, E AU - Nikiphorou, E TI - Are we really what we eat? Nutrition and its role in the onset of rheumatoid arthritis J2 - Autoimmun Rev PY - 2018 VL - 17 SP - 1074 EP - 1077 UR - https://doi.org/10.1016/j.autrev.2018.05.009 ER - TY - JOUR LB - 10. AU - James, D AU - Young, A AU - Kulinskaya, E AU - Knight, E AU - Thompson, W AU - Ollier, W AU - Dixey, J TI - Early Rheumatoid Arthritis Study Group (ERAS), UK. Orthopaedic intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years J2 - Rheumatology PY - 2004 VL - 43 SP - 369 EP - 376 UR - https://doi.org/10.1093/rheumatology/keh059 ER - TY - JOUR LB - 11. AU - Raheel, S AU - Matteson, EL AU - Crowson, CS AU - Myasoedova, E TI - Improved flare and remission pattern in rheumatoid arthritis over recent decades: a population-based study J2 - Rheumatology PY - 2017 VL - 56 SP - 2154 EP - 2161 UR - https://doi.org/10.1093/rheumatology/kex352 ER - TY - GEN LB - 12. AU - National Institute for Health and Care Excellence (NICE) TI - Rheumatoid Arthritis in Adults: Management. CY - London PB - NICE PY - 2018 UR - www.nice.org.uk/guidance/ng100 Y2 - October 2018 ER - TY - JOUR LB - 13. AU - Aletaha, D AU - Neogi, T AU - Silman, AJ AU - Funovits, J AU - Felson, DT AU - Bingham, CO TI - 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative J2 - Ann Rheum Dis PY - 2010 VL - 69 SP - 1580 EP - 1588 UR - https://doi.org/10.1136/ard.2010.138461 ER - TY - JOUR LB - 14. AU - Symmons, D AU - Turner, G AU - Webb, R AU - Asten, P AU - Barrett, E AU - Lunt, M TI - The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century J2 - Rheumatology PY - 2002 VL - 41 SP - 793 EP - 800 UR - https://doi.org/10.1093/rheumatology/41.7.793 ER - TY - JOUR LB - 15. AU - Symmons, DP AU - Barrett, EM AU - Bankhead, CR AU - Scott, DG AU - Silman, AJ TI - The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register J2 - Br J Rheumatol PY - 1994 VL - 33 SP - 735 EP - 739 UR - https://doi.org/10.1093/rheumatology/33.8.735 ER - TY - JOUR LB - 16. AU - Kearsley-Fleet, L AU - Davies, R AU - De Cock, D AU - Watson, KD AU - Lunt, M AU - Buch, MH TI - Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis J2 - Ann Rheum Dis PY - 2018 VL - 77 SP - 1405 EP - 1412 UR - https://doi.org/10.1136/annrheumdis-2018-213378 ER - TY - THES LB - 17. AU - Gavan, S TI - An Economic Evaluation of a Biomarker Test to Stratify Treatment for Rheumatoid Arthritis. CY - Manchester PB - University of Manchester PY - 2017 ER - TY - JOUR LB - 18. AU - Abhishek, A AU - Nakafero, G AU - Kuo, CF AU - Mallen, C AU - Zhang, W AU - Grainge, MJ AU - Doherty, M TI - Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink J2 - Rheumatology PY - 2018 VL - 57 SP - 977 EP - 981 UR - https://doi.org/10.1093/rheumatology/key013 ER - TY - JOUR LB - 19. AU - Hyrich, K AU - Symmons, D AU - Watson, K AU - Silman, A AU - BSRBR Control Centre Consortium TI - Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register J2 - Ann Rheum Dis PY - 2006 VL - 65 SP - 895 EP - 898 UR - https://doi.org/10.1136/ard.2005.043158 ER - TY - ELEC LB - 20. AU - National Rheumatoid Arthritis Society TI - The Economic Burden of Rheumatoid Arthritis UR - www.nras.org.uk/data/files/.../1_economic_burden_of_ra_final_30_3_10.pdf M1 - November 2018 ER - TY - ELEC LB - 21. AU - Joint Formulary Committee TI - British National Formulary CY - London PB - BMJ Group and Pharmaceutical Press UR - www.bnf.org/products/bnf-online/ M1 - December 2018 ER - TY - JOUR LB - 22. AU - Brown, EB AU - Earl, S AU - Haigh, R AU - Mascarenhas, R TI - Adherence to biologic therapies in patients with inflammatory arthritis J2 - Rheumatology PY - 2015 VL - 54 SP - i71 ER - TY - GEN LB - 23. AU - National Institute of Health and Care Excellence (NICE) TI - Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for Rheumatoid Arthritis not Previously Treated with DMARDs or After Conventional DMARDs only have Failed. CY - London PB - NICE PY - 2016 UR - www.nice.org.uk/guidance/ta375 Y2 - July 2019 ER - TY - ELEC LB - 24. AU - National Institute of Health and Care Excellence (NICE) TI - NICE Pathways TI - Rheumatoid Arthritis Overview. UR - https://pathways.nice.org.uk/pathways/rheumatoid-arthritis M1 - December 2018 ER - TY - JOUR LB - 25. AU - Cantini, F AU - Benucci, M TI - Focus on biosimilar etanercept – bioequivalence and interchangeability J2 - Biologics PY - 2018 VL - 12 SP - 87 EP - 95 UR - https://doi.org/10.2147/BTT.S126854 ER - TY - JOUR LB - 26. AU - Bruce, B AU - Fries, JF TI - The Health Assessment Questionnaire (HAQ) J2 - Clin Exp Rheumatol PY - 2005 VL - 23 SP - S14 EP - S18 ER - TY - JOUR LB - 27. AU - Prevoo, ML AU - van’T Hof, MA AU - Kuper, HH AU - van Leeuwen, MA AU - van de Putte, LB AU - van Riel, PL TI - Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis J2 - Arthritis Rheum PY - 1995 VL - 38 SP - 44 EP - 48 UR - https://doi.org/10.1002/art.1780380107 ER - TY - JOUR LB - 28. AU - Aletaha, D AU - Smolen, J TI - The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis J2 - Clin Exp Rheumatol PY - 2005 VL - 23 IS - Suppl. 5 SP - 100 EP - 108 ER - TY - JOUR LB - 29. AU - Felson, DT AU - Anderson, JJ AU - Boers, M AU - Bombardier, C AU - Furst, D AU - Goldsmith, C TI - American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis J2 - Arthritis Rheum PY - 1995 VL - 38 SP - 727 EP - 735 UR - https://doi.org/10.1002/art.1780380602 ER - TY - JOUR LB - 30. AU - van Gestel, AM AU - Prevoo, ML AU - van’T Hof, MA AU - van Rijswijk, MH AU - van de Putte, LB AU - van Riel, PL AU - Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis TI - Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria J2 - Arthritis Rheum PY - 1996 VL - 39 SP - 34 EP - 40 UR - https://doi.org/10.1002/art.1780390105 ER - TY - JOUR LB - 31. AU - Simpson, E AU - Hock, E AU - Stevenson, M AU - Wong, R AU - Dracup, N AU - Wailoo, A TI - What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis J2 - Health Technol Assess PY - 2018 VL - 22 IS - 20 UR - https://doi.org/10.3310/hta22200 ER - TY - ELEC LB - 32. AU - National Rheumatoid Arthritis Society TI - The DAS28 Score UR - www.nras.org.uk/the-das28-score M1 - November 2018 ER - TY - JOUR LB - 33. AU - Fransen, J AU - van Riel, PL TI - The Disease Activity Score and the EULAR response criteria J2 - Clin Exp Rheumatol PY - 2005 VL - 23 SP - 93 EP - 99 ER - TY - JOUR LB - 34. AU - Stevenson, M AU - Archer, R AU - Tosh, J AU - Simpson, E AU - Everson-Hock, E AU - Stevens, J TI - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation J2 - Health Technol Assess PY - 2016 VL - 20 IS - 35 UR - https://doi.org/10.3310/hta20350 ER - TY - JOUR LB - 35. AU - Vogelzang, EH AU - Hebing, RCF AU - Nurmohamed, MT AU - van Kuijk, AWR AU - Kruijff, JWF AU - l’Ami, MJ TI - Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up J2 - PLOS ONE PY - 2018 VL - 13 SP - e0205125 UR - https://doi.org/10.1371/journal.pone.0205125 ER - TY - GEN LB - 36. AU - National Institute of Health and Care Excellence (NICE) TI - Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a TNF Inhibitor CY - London PB - NICE PY - 2010 ER - TY - JOUR LB - 37. AU - Jani, M AU - Gavan, S AU - Chinoy, H AU - Dixon, WG AU - Harrison, B AU - Moran, A TI - A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice J2 - Rheumatology PY - 2016 VL - 55 SP - 2131 EP - 2137 UR - https://doi.org/10.1093/rheumatology/kew292 ER - TY - BOOK LB - 38. AU - Higgins, JPT AU - Green, S TI - The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. CY - Chichester PB - John Wiley & Sons Ltd PY - 2008 UR - https://doi.org/10.1002/9780470712184 ER - TY - JOUR LB - 39. AU - Moher, D AU - Liberati, A AU - Tetzlaff, J AU - Altman, DG AU - PRISMA Group TI - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement J2 - PLOS Med PY - 2009 VL - 6 SP - e1000097 UR - https://doi.org/10.1371/journal.pmed.1000097 ER - TY - JOUR LB - 40. AU - Higgins, JP AU - Altman, DG AU - Gøtzsche, PC AU - Jüni, P AU - Moher, D AU - Oxman, AD TI - The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials J2 - BMJ PY - 2011 VL - 343 SP - d5928 UR - https://doi.org/10.1136/bmj.d5928 ER - TY - JOUR LB - 41. AU - Sterne, JA AU - Hernán, MA AU - Reeves, BC AU - Savović, J AU - Berkman, ND AU - Viswanathan, M TI - ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions J2 - BMJ PY - 2016 VL - 355 SP - i4919 UR - https://doi.org/10.1136/bmj.i4919 ER - TY - JOUR LB - 42. AU - Ucar, E AU - Gorostiza, I AU - Gomez, C AU - Perez, C AU - Dios, J AU - Alvarez, B TI - Prospective, intervention, multicenter study of utility of biologic drug monitoring with respect to the efficacy and cost of adalimumab tapering in patients with rheumatic diseases: preliminary results of ingebio study J2 - Ann Rheum Dis PY - 2017 VL - 76 SP - 826 UR - https://doi.org/10.1136/annrheumdis-2017-eular.4785 ER - TY - JOUR LB - 43. AU - Arango, CG AU - Vivar, MLG AU - Angulo, EU AU - Gorostiza, I AU - Perez, CE AU - De Dios, JR TI - Prospective, intervention, multicenter, non-inferiority study of utility of therapeutic drug monitoring with respect to the efficacy and cost of adalimumab tapering in patients with rheumatic diseases J2 - Arthritis Rheum PY - 2017 VL - 69 IS - Suppl. 10 ER - TY - JOUR LB - 44. AU - Pascual-Salcedo, D AU - Plasencia, C AU - Gonzalez Del Valle, L AU - Lopez Casla, T AU - Arribas, F AU - Villalba, A TI - Therapeutic drug monitoring (TDM) in rheumatic day clinic enables to reduce pharmaceutical cost maintaining clinical efficacy J2 - Ann Rheum Dis PY - 2013 VL - 72 SP - A227 UR - https://doi.org/10.1136/annrheumdis-2013-eular.717 ER - TY - JOUR LB - 45. AU - Gorostiza, I AU - Angulo, EU AU - Arango, CG AU - Perez, CE AU - De Dios, JR AU - Alvarez, B TI - Prospective, intervention, multicenter study of utility of biologic drug monitoring with respect to the efficacy and cost of adalimumab tapering in patients with rheumatic diseases (34-week descriptive data) [abstract] J2 - Arthritis Rheum PY - 2016 VL - 68 IS - Suppl. 10 SP - 835 EP - 836 ER - TY - ELEC LB - 46. AU - Haavardsholm, EA TI - The Norwegian Drug Monitoring Study (NOR-DRUM). PY - 2018 UR - https://clinicaltrials.gov/ct2/show/NCT03074656 M1 - December 2018 ER - TY - JOUR LB - 47. AU - van der Maas, A AU - Lie, E AU - Christensen, R AU - Choy, E AU - de Man, YA AU - van Riel, P TI - Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study J2 - Ann Rheum Dis PY - 2013 VL - 72 SP - 1800 EP - 1805 UR - https://doi.org/10.1136/annrheumdis-2012-202281 ER - TY - GEN LB - 48. AU - National Institute for Health and Care Excellence (NICE) TI - Therapeutic Monitoring of TNF-alpha Inhibitors in Rheumatoid Arthritis. CY - London PB - NICE PY - 2019 UR - www.nice.org.uk/guidance/dg36/documents/final-scope Y2 - February 2020 ER - TY - JOUR LB - 49. AU - Evers, S AU - Goossens, M AU - de Vet, H AU - van Tulder, M AU - Ament, A TI - Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria J2 - Int J Technol Assess Health Care PY - 2005 VL - 21 SP - 240 EP - 245 UR - https://doi.org/10.1017/S0266462305050324 ER - TY - JOUR LB - 50. AU - Philips, Z AU - Bojke, L AU - Sculpher, M AU - Claxton, K AU - Golder, S TI - Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment J2 - PharmacoEconomics PY - 2006 VL - 24 SP - 355 EP - 371 UR - https://doi.org/10.2165/00019053-200624040-00006 ER - TY - JOUR LB - 51. AU - Krieckaert, C AU - Nair, SC AU - Nurmohamed, MT AU - Van Dongen, CJ AU - Lems, WF AU - Lafeber, FP TI - Evaluating the cost-effectiveness of personalized treatment with adalimumab using serum drug level and anti-adalimumab antibodies in rheumatoid arthritis patients J2 - Ann Rheum Dis PY - 2013 VL - 71 SP - 104 UR - https://doi.org/10.1136/annrheumdis-2012-eular.1832 ER - TY - JOUR LB - 52. AU - Krieckaert, CLM AU - Nair, SC AU - Nurmohamed, MT AU - van Dongen, CJJ AU - Lems, WF AU - Lafeber, FPJG TI - Evaluating the cost-effectiveness of personalized treatment with adalimumab using serum drug levels in rheumatoid arthritis patients J2 - Arthritis Rheum-Us PY - 2012 VL - 64 SP - S779 ER - TY - JOUR LB - 53. AU - Krieckaert, CL AU - Nair, SC AU - Nurmohamed, MT AU - van Dongen, CJJ AU - Lems, WF AU - Lafeber, FPJG TI - Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects J2 - Ann Rheum Dis PY - 2015 VL - 74 SP - 361 EP - 368 UR - https://doi.org/10.1136/annrheumdis-2013-204101 ER - TY - JOUR LB - 54. AU - Laine, J AU - Jokiranta, TS AU - Eklund, KK AU - Väkeväinen, M AU - Puolakka, K TI - Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers J2 - Biologics PY - 2016 VL - 10 SP - 67 EP - 73 UR - https://doi.org/10.2147/BTT.S96982 ER - TY - JOUR LB - 55. AU - Bartelds, GM AU - Krieckaert, CL AU - Nurmohamed, MT AU - van Schouwenburg, PA AU - Lems, WF AU - Twisk, JW TI - Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up J2 - JAMA PY - 2011 VL - 305 SP - 1460 EP - 1468 UR - https://doi.org/10.1001/jama.2011.406 ER - TY - BOOK LB - 56. AU - Oostenbrink, JB AU - Koopmanschap, MA AU - Rutten, FFH TI - Guideline for Cost-Of-Illness Study; Methods and Guideline-Rates for Economic Evaluations in Health Care. Guideline for Cost-Of-Illness Study CY - Amstelveen PB - College voor Zorgverzekeringen PY - 2000 ER - TY - JOUR LB - 57. AU - Vincent, FB AU - Morand, EF AU - Murphy, K AU - Mackay, F AU - Mariette, X AU - Marcelli, C TI - Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective J2 - Ann Rheum Dis PY - 2013 VL - 72 SP - 165 EP - 178 UR - https://doi.org/10.1136/annrheumdis-2012-202545 ER - TY - BOOK LB - 58. AU - Hujanen, T AU - Kapiainen, S AU - Tuominen, U AU - Pekurinen, M TI - Terveydenhuollon yksikkökustannukset Suomessa vuonna 2006 CY - Työpapereita/Stakes PB - Helsinki: Stakes PY - 2008 UR - http://urn.fi/URN:NBN:-fi-fe201204194178 Y2 - August 2015 ER - TY - JOUR LB - 59. AU - Malottki, K AU - Barton, P AU - Tsourapas, A AU - Uthman, AO AU - Liu, Z AU - Routh, K TI - Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation J2 - Health Technol Assess PY - 2011 VL - 15 IS - 14 UR - https://doi.org/10.3310/hta15140 ER - TY - GEN LB - 60. AU - Department of Health and Social Care (DHSC) TI - NHS Reference Costs 2015–16. CY - London PB - DHSC PY - 2016 ER - TY - ELEC LB - 61. AU - NHS Lambeth Clinical Commissioning Group TI - Ensuring the Value of Clinical Commissioning Group (CCG) Commissioned Biologics Medicines – Biologics Value Tariff Agreement. UR - www.lambethccg.nhs.uk/news-and-publications/meeting-papers/lambeth-borough-prescribing-committee/Lambeth%20Borough%20Prescribing%20Committee/Prescribing%20Rebates/Biologics%20Value%20Agreement%202017-19%20FINAL.pdf M1 - December 2018 ER - TY - ELEC LB - 62. AU - NHS England TI - Regional Medicines Optimisation Committee Briefing Best Value Biologicals: Adalimumab Update 3 PY - 2018 UR - www.sps.nhs.uk/wp-content/uploads/2018/07/Adalimumab-RMOC-Briefing-Final-July.pdf M1 - December 2018 ER - TY - ELEC LB - 63. AU - NHS England and NHS Improvement TI - Commissioning Framework for Biological Medicines (Including Biosimilar Medicines). PY - 2017 UR - www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf M1 - December 2018 ER - TY - ELEC LB - 64. AU - NHS Business Services Authority TI - Medicines Optimisation Dashboard UR - www.nhsbsa.nhs.uk/epact2/dashboards-and-specifications/medicines-optimisation-dashboard M1 - November 2018 ER - TY - JOUR LB - 65. AU - Verhoef, LM AU - Tweehuysen, L AU - Hulscher, ME AU - Fautrel, B AU - den Broeder, AA TI - bDMARD dose reduction in rheumatoid arthritis: a narrative review with systematic literature search J2 - Rheumatol Ther PY - 2017 VL - 4 SP - 1 EP - 24 UR - https://doi.org/10.1007/s40744-017-0055-5 ER - TY - JOUR LB - 66. AU - Smolen, JS AU - Jones, H AU - Mahgoub, E AU - Pedersen, R AU - Marshall, L TI - Association between flare and radiographic progression in patients with rheumatoid arthritis [abstract] J2 - Ann Rheum Dis PY - 2017 VL - 76 IS - Suppl. 2 UR - https://doi.org/10.1136/annrheumdis-2017-eular.1854 ER - TY - ELEC LB - 67. AU - University of Manchester TI - BSRBR-RA Database UR - www.bsrbr.org/database/ M1 - April 2020 ER - TY - JOUR LB - 68. AU - Dennison, EM AU - Packham, J AU - Hyrich, K TI - The BSRBR-RA at 15 years J2 - Rheumatology PY - 2016 VL - 55 SP - 2093 EP - 2095 UR - https://doi.org/10.1093/rheumatology/kew053 ER - TY - GEN LB - 69. AU - National Institute for Health and Care Excellence (NICE) TI - Guide to the Methods of Technology Appraisal 2013 CY - London PB - NICE PY - 2013 UR - www.nice.org.uk/process/pmg9/chapter/foreword Y2 - December 2018 ER - TY - JOUR LB - 70. AU - Bykerk, VP AU - Shadick, N AU - Frits, M AU - Bingham, CO AU - Jeffery, I AU - Iannaccone, C TI - Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry J2 - J Rheumatol PY - 2014 VL - 41 SP - 227 EP - 234 UR - https://doi.org/10.3899/jrheum.121521 ER - TY - JOUR LB - 71. AU - Bingham, CO AU - Pohl, C AU - Woodworth, TG AU - Hewlett, SE AU - May, JE AU - Rahman, MU TI - Developing a standardized definition for disease ‘flare’ in rheumatoid arthritis (OMERACT 9 Special Interest Group) J2 - J Rheumatol PY - 2009 VL - 36 SP - 2335 EP - 2341 UR - https://doi.org/10.3899/jrheum.090369 ER - TY - JOUR LB - 72. AU - Markusse, IM AU - Dirven, L AU - Gerards, AH AU - van Groenendael, JH AU - Ronday, HK AU - Kerstens, PJ TI - Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study J2 - Arthritis Res Ther PY - 2015 VL - 17 SP - 232 UR - https://doi.org/10.1186/s13075-015-0730-2 ER - TY - JOUR LB - 73. AU - Senabre Gallego, JM AU - Rosas Gomez De Salazar, J AU - Marco Mingot, M AU - Naranjo, A AU - Llinares-Tello, F AU - Pons, A TI - Clinical activity, ultrasound assessment and drug monitoring in rheumatoid arthritis patients receiving anti-TNF-alpha therapy with extended interval of administration J2 - Ann Rheum Dis PY - 2017 VL - 76 SP - 1016 UR - https://doi.org/10.1136/annrheumdis-2017-eular.3066 ER - TY - JOUR LB - 74. AU - Lahiri, M AU - Dixon, WG TI - Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis J2 - Best Pract Res Clin Rheumatol PY - 2015 VL - 29 SP - 290 EP - 305 UR - https://doi.org/10.1016/j.berh.2015.05.009 ER - TY - JOUR LB - 75. AU - Bruce, ES AU - Kearsley-Fleet, L AU - Watson, KD AU - Symmons, DP AU - Hyrich, KL TI - Risk ofPneumocystis jiroveciipneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis J2 - Rheumatology PY - 2016 VL - 55 SP - 1336 EP - 1337 UR - https://doi.org/10.1093/rheumatology/kew200 ER - TY - JOUR LB - 76. AU - Dixon, WG AU - Hyrich, KL AU - Watson, KD AU - Lunt, M AU - Galloway, J AU - Ustianowski, A AU - Symmons, DP TI - BSRBR Control Centre Consortium TI - Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) J2 - Ann Rheum Dis PY - 2010 VL - 69 SP - 522 EP - 528 UR - https://doi.org/10.1136/ard.2009.118935 ER - TY - JOUR LB - 77. AU - Burmester, GR AU - Landewé, R AU - Genovese, MC AU - Friedman, AW AU - Pfeifer, ND AU - Varothai, NA AU - Lacerda, AP TI - Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis J2 - Ann Rheum Dis PY - 2017 VL - 76 SP - 414 EP - 417 UR - https://doi.org/10.1136/annrheumdis-2016-209322 ER - TY - JOUR LB - 78. AU - Singh, JA AU - Wells, GA AU - Christensen, R AU - Tanjong Ghogomu, E AU - Maxwell, L AU - Macdonald, JK TI - Adverse effects of biologics: a network meta-analysis and Cochrane overview J2 - Cochrane Database Syst Rev PY - 2011 VL - 2 UR - https://doi.org/10.1002/14651858.CD008794.pub2 ER - TY - JOUR LB - 79. AU - Singh, JA AU - Cameron, C AU - Noorbaloochi, S AU - Cullis, T AU - Tucker, M AU - Christensen, R TI - Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis J2 - Lancet PY - 2015 VL - 386 SP - 258 EP - 265 UR - https://doi.org/10.1016/S0140-6736(14)61704-9 ER - TY - JOUR LB - 80. AU - Maravic, M AU - Bergé, C AU - Daurès, JP AU - Boissier, MC TI - Practices for managing a flare of long-standing rheumatoid arthritis: survey among French rheumatologists J2 - Clin Exp Rheumatol PY - 2005 VL - 23 SP - 36 EP - 42 ER - TY - BOOK LB - 81. AU - Curtis, L AU - Burns, A TI - Unit Costs of Health and Social Care 2017 CY - Canterbury PB - PSSRU, University of Kent PY - 2017 ER - TY - JOUR LB - 82. AU - Barbieri, M AU - Wong, JB AU - Drummond, M TI - The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK J2 - PharmacoEconomics PY - 2005 VL - 23 SP - 607 EP - 618 UR - https://doi.org/10.2165/00019053-200523060-00007 ER - TY - JOUR LB - 83. AU - Radner, H AU - Smolen, JS AU - Aletaha, D TI - Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs J2 - Arthritis Res Ther PY - 2014 VL - 16 SP - R56 UR - https://doi.org/10.1186/ar4491 ER - TY - ELEC LB - 84. AU - NHS Improvment TI - Archived Reference Costs UR - https://improvement.nhs.uk/resources/reference-costs/ M1 - December 2018 ER - TY - JOUR LB - 85. AU - Oppong, R AU - Kaambwa, B AU - Nuttall, J AU - Hood, K AU - Smith, RD AU - Coast, J TI - The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries J2 - Eur J Health Econ PY - 2013 VL - 14 SP - 197 EP - 209 UR - https://doi.org/10.1007/s10198-011-0360-9 ER - TY - ELEC LB - 86. AU - The Campbell and Cochrane Economics Methods Group (CCEMG) and the Evidence for Policy and Practice Information and Coordinating Centre (EPPI Centre) TI - CCEMG–EPPI-Centre Cost Converter UR - https://eppi.ioe.ac.uk/costconversion/default.aspx M1 - December 2018 ER - TY - JOUR LB - 87. AU - Smolen, JS AU - Nash, P AU - Durez, P AU - Hall, S AU - Ilivanova, E AU - Irazoque-Palazuelos, F TI - Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial J2 - Lancet PY - 2013 VL - 381 SP - 918 EP - 929 UR - https://doi.org/10.1016/S0140-6736(12)61811-X ER - TY - GEN LB - 88. AU - National Institute for Health and Care Excellence (NICE) TI - Tocilizumab for the Treatment of Rheumatoid Arthritis [TA247] CY - London PB - NICE PY - 2012 UR - www.nice.org.uk/guidance/ta247 Y2 - December 2018 ER - TY - ELEC LB - 89. AU - Datapharm TI - Remicade 100mg Powder for Concentrate for Solution for Infusion. UR - www.medicines.org.uk/emc/product/3831/smpc M1 - December 2018 ER - TY - GEN LB - 90. AU - National Institute for Health and Care Excellence (NICE) TI - Therapeutic Monitoring of TNF-alpha Inhibitors in Crohn’s Disease (LISA-TRACKER ELISA Kits, IDKmonitor ELISA Kits, and Promonitor ELISA kits) [DG22] CY - London PB - NICE PY - 2016 UR - www.nice.org.uk/guidance/dg22 Y2 - December 2018 ER - TY - GEN LB - 91. AU - National Institute for Health and Care Excellence (NICE) TI - Infliximab, Adalimumab And Golimumab for Treating Moderately to Severely Active Ulcerative Colitis after the Failure of Conventional Therapy [TA329]. CY - London PB - NICE PY - 2015 UR - www.nice.org.uk/guidance/ta329 Y2 - December 2018 ER - TY - ELEC LB - 92. AU - Royal Mail TI - Get a Price. UR - www.royalmail.com/price-finder/ M1 - December 2018 ER - TY - JOUR LB - 93. AU - Rosas, J AU - Llinares-Tello, F AU - Miguel Senabre, J AU - Santos-Soler, G AU - Salas-Heredia, E AU - Barber, X TI - Economic impact of decreasing adalimumab and etanercept doses and drug monitoring in patients with rheumatoid arthritis in clinical remission: preliminary study from a local biologics unit [abstract] J2 - Arthritis Rheumatol PY - 2015 VL - 67 IS - Suppl. 10 ER - TY - JOUR LB - 94. AU - Chen, DY AU - Chen, YM AU - Hsieh, TY AU - Hung, WT AU - Hsieh, CW AU - Chen, HH TI - Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up J2 - Rheumatology PY - 2016 VL - 55 SP - 143 EP - 148 UR - https://doi.org/10.1093/rheumatology/kev298 ER - TY - JOUR LB - 95. AU - Kobelt, G AU - Lindgren, P AU - Lindroth, Y AU - Jacobson, L AU - Eberhardt, K TI - Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis J2 - Rheumatology PY - 2005 VL - 44 SP - 1169 EP - 1175 UR - https://doi.org/10.1093/rheumatology/keh703 ER - TY - JOUR LB - 96. AU - Burn, E AU - Edwards, CJ AU - Murray, DW AU - Silman, A AU - Cooper, C AU - Arden, NK TI - Trends and determinants of length of stay and hospital reimbursement following knee and hip replacement: evidence from linked primary care and NHS hospital records from 1997 to 2014 J2 - BMJ Open PY - 2018 VL - 8 SP - e019146 UR - https://doi.org/10.1136/bmjopen-2017-019146 ER - TY - ELEC LB - 97. AU - NHS TI - National Schedule of Reference Costs Year: 2010–11 NHS Trusts and PCTS Combined HRG Data PY - 2013 UR - https://data.gov.uk/dataset/7fa41b07-a296-47c7-b74b-40ec3a102e6a/nhs-reference-costs-2010-11 M1 - November 2018 ER - TY - JOUR LB - 98. AU - Wells, G AU - Becker, JC AU - Teng, J AU - Dougados, M AU - Schiff, M AU - Smolen, J TI - Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate J2 - Ann Rheum Dis PY - 2009 VL - 68 SP - 954 EP - 960 UR - https://doi.org/10.1136/ard.2007.084459 ER - TY - JOUR LB - 99. AU - Fleischmann, RM AU - van der Heijde, D AU - Gardiner, PV AU - Szumski, A AU - Marshall, L AU - Bananis, E TI - DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable J2 - RMD Open PY - 2017 VL - 3 SP - e000382 UR - https://doi.org/10.1136/rmdopen-2016-000382 ER - TY - JOUR LB - 100. AU - Barnabe, C AU - Thanh, NX AU - Ohinmaa, A AU - Homik, J AU - Barr, SG AU - Martin, L AU - Maksymowych, WP TI - Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission J2 - Ann Rheum Dis PY - 2013 VL - 72 SP - 1664 EP - 1668 UR - https://doi.org/10.1136/annrheumdis-2012-201918 ER - TY - JOUR LB - 101. AU - Aletaha, D AU - Funovits, J AU - Keystone, EC AU - Smolen, JS TI - Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients J2 - Arthritis Rheum PY - 2007 VL - 56 SP - 3226 EP - 3235 UR - https://doi.org/10.1002/art.22943 ER - TY - JOUR LB - 102. AU - Pennington, B AU - Davis, S TI - Mapping from the Health Assessment Questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results J2 - Value Health PY - 2014 VL - 17 SP - 762 EP - 771 UR - https://doi.org/10.1016/j.jval.2014.11.002 ER - TY - JOUR LB - 103. AU - Bansback, N AU - Marra, C AU - Tsuchiya, A AU - Anis, A AU - Guh, D AU - Hammond, T AU - Brazier, J TI - Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis J2 - Arthritis Rheum PY - 2007 VL - 57 SP - 963 EP - 971 UR - https://doi.org/10.1002/art.22885 ER - TY - JOUR LB - 104. AU - Kobelt, G AU - Jönsson, L AU - Lindgren, P AU - Young, A AU - Eberhardt, K TI - Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis J2 - Arthritis Rheum PY - 2002 VL - 46 SP - 2310 EP - 2319 UR - https://doi.org/10.1002/art.10471 ER - TY - JOUR LB - 105. AU - Hurst, NP AU - Kind, P AU - Ruta, D AU - Hunter, M AU - Stubbings, A TI - Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D) J2 - Br J Rheumatol PY - 1997 VL - 36 SP - 551 EP - 559 UR - https://doi.org/10.1093/rheumatology/36.5.551 ER - TY - JOUR LB - 106. AU - Hernández Alava, M AU - Wailoo, A AU - Wolfe, F AU - Michaud, K TI - The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis J2 - Rheumatology PY - 2013 VL - 52 SP - 944 EP - 950 UR - https://doi.org/10.1093/rheumatology/kes400 ER - TY - JOUR LB - 107. AU - Goh, L AU - Jewell, T AU - Laversuch, C AU - Samanta, A TI - A systematic review of the influence of anti-TNF on infection rates in patients with rheumatoid arthritis J2 - Rev Bras Reumatol PY - 2013 VL - 53 SP - 501 EP - 515 UR - https://doi.org/10.1016/j.rbr.2012.12.001 ER - TY - JOUR LB - 108. AU - Listing, J AU - Gerhold, K AU - Zink, A TI - The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment J2 - Rheumatology PY - 2013 VL - 52 SP - 53 EP - 61 UR - https://doi.org/10.1093/rheumatology/kes305 ER - TY - JOUR LB - 109. AU - Gülfe, A AU - Wallman, JK AU - Kristensen, LE TI - EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden J2 - Arthritis Res Ther PY - 2016 VL - 18 SP - 51 UR - https://doi.org/10.1186/s13075-016-0950-0 ER - TY - JOUR LB - 110. AU - Gülfe, A AU - Kristensen, LE AU - Saxne, T AU - Jacobsson, LT AU - Petersson, IF AU - Geborek, P TI - Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden J2 - Ann Rheum Dis PY - 2010 VL - 69 SP - 352 EP - 357 UR - https://doi.org/10.1136/ard.2008.103473 ER - TY - JOUR LB - 111. AU - Paramarta, JE AU - De Rycke, L AU - Ambarus, CA AU - Tak, PP AU - Baeten, D TI - Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment J2 - Rheumatology PY - 2013 VL - 52 SP - 1873 EP - 1878 UR - https://doi.org/10.1093/rheumatology/ket239 ER - TY - JOUR LB - 112. AU - Jani, M AU - Chinoy, H AU - Warren, RB AU - Griffiths, CE AU - Plant, D AU - Fu, B TI - Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis J2 - Arthritis Rheum PY - 2015 VL - 67 SP - 2011 EP - 2019 UR - https://doi.org/10.1002/art.39169 ER - TY - JOUR LB - 113. AU - Jani, M AU - Isaacs, JD AU - Morgan, AW AU - Wilson, AG AU - Plant, D AU - Hyrich, KL TI - High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort J2 - Ann Rheum Dis PY - 2017 VL - 76 SP - 208 EP - 213 UR - https://doi.org/10.1136/annrheumdis-2015-208849 ER - TY - JOUR LB - 114. AU - l’Ami, MJ AU - Krieckaert, CL AU - Nurmohamed, MT AU - van Vollenhoven, RF AU - Rispens, T AU - Boers, M AU - Wolbink, GJ TI - Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial J2 - Ann Rheum Dis PY - 2018 VL - 77 SP - 484 EP - 487 UR - https://doi.org/10.1136/annrheumdis-2017-211781 ER - TY - JOUR LB - 115. AU - Ara, R AU - Brazier, JE TI - Populating an economic model with health state utility values: moving toward better practice J2 - Value Health PY - 2010 VL - 13 SP - 509 EP - 518 UR - https://doi.org/10.1111/j.1524-4733.2010.00700.x ER - TY - JOUR LB - 116. AU - Jani, M AU - Dixon, WG AU - Lunt, M AU - De Cock, D AU - Isaacs, JD AU - Morgan, AW TI - The association of biologic drug-levels with infection risk: results from the british society for rheumatology biologics register for rheumatoid arthritis J2 - Ann Rheum Dis PY - 2018 VL - 77 SP - 163 EP - 164 UR - https://doi.org/10.1136/annrheumdis-2018-eular.1946 ER - TY - BOOK LB - 117. AU - Dias, S AU - Welton, NJ AU - Sutton, AJ AU - Caldwell, DM AU - Lu, G AU - Ades, AE TI - NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials CY - London PB - NICE PY - 2014 ER - TY - ELEC LB - 118. AU - NHS Greater Glasgow and Clyde TI - Rheumatology Biologic Drug Monitoring Recommendations. UR - www.nhsggc.org.uk/media/246324/rheumatology-biologic-drug-monitoring-recommendations-september-2017.pdf M1 - November 2018 ER - TY - JOUR LB - 119. AU - Pouw, MF AU - Krieckaert, CL AU - Nurmohamed, MT AU - van der Kleij, D AU - Aarden, L AU - Rispens, T AU - Wolbink, G TI - Key findings towards optimising adalimumab treatment: the concentration-effect curve J2 - Ann Rheum Dis PY - 2015 VL - 74 SP - 513 EP - 518 UR - https://doi.org/10.1136/annrheumdis-2013-204172 ER - TY - JOUR LB - 120. AU - Pascual-Salcedo, D AU - Chamaida, P AU - Teresa, J AU - Del Valle, GL AU - Prado, S AU - Cristina, D TI - Dose-tapering of TNF inhibitors in daily rheumatology practice enables the maintenance of clinical efficacy while improving cost-effectiveness J2 - Pharmacovigilance PY - 2015 VL - 3 SP - 172 UR - https://doi.org/10.4172/2329-6887.1000172 ER -